☆ 4.6 Article

Therapeutic potential of the novel Bcl-2/Bcl-XL dual inhibitor, APG1252, alone or in combination against non-small cell lung cancer

MOLECULAR CARCINOGENESIS (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Add to Collection

Meeting Abstract Hematology

Dual BCL-2/BCL-XL Inhibitor Pelcitoclax (APG-1252) Overcomes Intrinsic and Acquired Resistance to Venetoclax in Multiple Myeloma Cells

Leona Yamamoto et al.

BLOOD (2021)

Add to Collection

Article Oncology

Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)

Erin M. Bertino et al.

Summary: The study evaluated the safety and efficacy of combination therapy with osimertinib and navitoclax in advanced EGFR-mutant non-small cell lung cancer patients. Results demonstrated that the combination therapy was safe and effective at the recommended dose, with a high objective response rate of 100% in patients.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Review Chemistry, Medicinal

Development of Mcl-1 inhibitors for cancer therapy

Arvind Negi et al.

Summary: Mcl-1, an anti-apoptotic protein, plays a crucial role in cancer cell survival and is a promising target for cancer therapy. Various inhibitors targeting Mcl-1 have been designed, but none have been approved for clinical use. This review summarizes the structures and structure-activity relationships of Mcl-1 inhibitors, highlighting their potential in cancer treatment.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

MA02.06 Phase 1b Study of Pelcitoclax (APG-1252) in Combination With Osimertinib in Patients With EGFR TKI-Resistant NSCLC

L. Zhang et al.

Journal of Thoracic Oncology (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Targeting Bcl-2 for cancer therapy

Linlin Zhang et al.

Summary: Apoptosis deficiency is a crucial feature in neoplastic diseases, with the Bcl-2 family of proteins playing a decisive role in regulating apoptosis. Studies have shown that hyperactivation of Bcl-2 anti-apoptotic effects is associated with cancer occurrence and resistance to therapy, making targeting Bcl-2 inactivation a promising route for cancer treatment.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2021)

Add to Collection

Review Oncology

Targeting MCL-1 in cancer: current status and perspectives

Haolan Wang et al.

Summary: MCL-1, an antiapoptotic protein, is frequently overexpressed in many tumor types and closely associated with tumorigenesis, poor prognosis, and drug resistance. Its central role in regulating the mitochondrial apoptotic pathway makes it an attractive target for cancer therapy. Progress has been made towards MCL-1 inhibitors and some have entered clinical trials.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Article Oncology

Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib

Lei Zhu et al.

Summary: Osimertinib is a promising third-generation EGFR tyrosine kinase inhibitor for NSCLC but can lead to acquired resistance. The study reveals that modulation of c-Myc plays a critical role in therapeutic efficacy and targeting c-Myc may overcome acquired resistance, providing a potential strategy for further treatment.

CANCER RESEARCH (2021)

Add to Collection

Article Cell Biology

Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway

Fan Luo et al.

Summary: The combination of APG-1252 and gemcitabine exhibits synergistic anticancer activities against nasopharyngeal carcinoma (NPC), providing a promising treatment modality for patients. This combination enhanced NPC cell apoptosis and inhibited invasion, migration, and proliferation both in vitro and in vivo through various mechanisms including caspase-dependent pathways and blocking signaling pathways. Results suggest a potential new therapeutic strategy for advanced NPC.

CELL DEATH & DISEASE (2021)

Add to Collection

Review Cell Biology

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations

Kenichi Suda et al.

Summary: EGFR tyrosine kinase inhibitors are the standard of care for lung cancer patients with EGFR-activating mutations, but resistance to these inhibitors is almost inevitable. Drug-tolerant cells that survive early exposure to TKIs are hypothesized to be an important source of cancer cells that eventually develop irreversible resistance.

CELLS (2021)

Add to Collection

Article Oncology

Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer

Yingjie Lu et al.

Summary: The study identified that upregulation of Bcl-2 and Bcl-xL expression was associated with resistance to osimertinib in NSCLC cells. Targeting Bcl-2 and Bcl-xL using ABT-263 could resensitize resistant cells to osimertinib treatment and enhance cell apoptosis rate. These findings suggest a potential novel therapeutic strategy for overcoming resistance in NSCLC patients receiving EGFR TKIs.

MOLECULAR MEDICINE REPORTS (2021)

Add to Collection

Article Medicine, General & Internal

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

S. S. Ramalingam et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small-cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589)

Hongjing Zang et al.

CANCER (2020)

Add to Collection

Article Oncology

Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway

Kari J. Kurppa et al.

CANCER CELL (2020)

Add to Collection

Article Oncology

First-in-human study of palcitoclax (APG-1252), a novel dual Bcl-2/Bcl-xL inhibitor, demonstrated advantages in platelet safety while maintaining anticancer effect in U.S. patients with metastatic solid tumors.

Nehal J. Lakhani et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma

Hanjie Yi et al.

CANCER MEDICINE (2020)

Add to Collection

Article Toxicology

Synergistic effects of Bcl-2 inhibitors with AZD9291 on overcoming the acquired resistance of AZD9291 in H1975 cells

Zhongwei Liu et al.

ARCHIVES OF TOXICOLOGY (2020)

Add to Collection

Article Oncology

MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers

Jiajia Gu et al.

CANCER (2020)

Add to Collection

Article Oncology

Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma

Enyuan Shang et al.

CANCERS (2020)

Add to Collection

Review Oncology

Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review

Andrew J. Piper-Vallillo et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL

Georgia Greaves et al.

CELL DEATH AND DIFFERENTIATION (2019)

Add to Collection

Article Oncology

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

Suresh S. Ramalingam et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer

J. -C. Soria et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Multidisciplinary Sciences

Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity

Ryan S. Soderquist et al.

NATURE COMMUNICATIONS (2018)

Add to Collection

Article Oncology

APG-1252-12A induces mitochondria-dependent apoptosis through inhibiting the antiapoptotic proteins Bcl-2/Bcl-xl in HL-60 cells

Jing Wang et al.

INTERNATIONAL JOURNAL OF ONCOLOGY (2017)

Add to Collection

Review Medicine, General & Internal

Cellular Senescence: A Translational Perspective

James L. Kirkland et al.

EBIOMEDICINE (2017)

Add to Collection

Article Oncology

Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation

Puyu Shi et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection

Article Oncology

Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment

Puyu Shi et al.

CANCER LETTERS (2016)

Add to Collection

Article Biochemistry & Molecular Biology

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

Aaron N. Hata et al.

NATURE MEDICINE (2016)

Add to Collection

Editorial Material Medicine, General & Internal

Overcoming Resistance to Targeted Therapy for Lung Cancer

Ramaswamy Govindan

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Review Oncology

Broad targeting of resistance to apoptosis in cancer

Ramzi M. Mohammad et al.

SEMINARS IN CANCER BIOLOGY (2015)

Add to Collection

Review Cell Biology

Targeting extrinsic apoptosis in cancer: Challenges and opportunities

Simone Fulda

SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2015)

Add to Collection

Review Respiratory System

Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance

Alfredo Tartarone et al.

THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2015)

Add to Collection

Article Multidisciplinary Sciences

BM-1197: A Novel and Specific Bcl-2/Bcl-xL Inhibitor Inducing Complete and Long-Lasting Tumor Regression In Vivo

Longchuan Bai et al.

PLOS ONE (2014)

Add to Collection

Article Oncology

The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis

Hui Ren et al.

CANCER LETTERS (2013)

Add to Collection

Review Oncology

Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL)

Avi Ashkenazi et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

Add to Collection

Review Oncology

Targeted induction of apoptosis in cancer management: The emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents

EK Rowinsky

JOURNAL OF CLINICAL ONCOLOGY (2005)

Add to Collection

Review Oncology

Promoting apoptosis as a strategy for cancer drug discovery

SW Fesik

NATURE REVIEWS CANCER (2005)

Add to Collection

Article Biochemistry & Molecular Biology

Blocking anti-apoptosis as a strategy for cancer chemotherapy:: NF-κB as a target

NR Monks et al.

JOURNAL OF CELLULAR BIOCHEMISTRY (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.